
|Articles|June 17, 2022
Daily Medication Pearl: Buprenorphine (Butrans)
Author(s)Saro Arakelians, PharmD
Buprenorphine (Butrans) is a partial opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.
Advertisement
Medication Pearl of the Day: Buprenorphine (Butrans)
Indication: Buprenorphine (Butrans) is a partial opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.
Insight:
- Dosing: Doses of 7.5, 10, 15, and 20 mcg/hour are for opioid experienced patients only.
- Dosage forms: Transdermal system 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour, and 20 mcg/hour.
- Adverse events: Most common adverse reactions (≥ 5%) include nausea, headache, application site pruritus, dizziness, constipation, somnolence, vomiting, application site erythema, dry mouth, and application site rash.
- Mechanism of action: Buprenorphine is a partial agonist at mu opioid receptors.
Source:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updates in Treatment of Unresectable Hepatocellular Carcinoma
2
FDA Approves Rucaparib for the Treatment of Adults With mCRPC
3
Infliximab and Adalimumab Biosimilars Maintain Comparable Safety, Efficacy, Immunogenicity in IBD
4
Notable Updates in Medication Therapy Management in 2025
5











































































































































































































